Indian J Pharm Close
 

Figure 2: Focal subtle atypia in biopsy-proven high-grade urothelial carcinoma cases with initial negative high-grade urothelial carcinoma, (a) acute inflammation, crystals, reactive cells (curved arrow). Nuclear–cytoplasmic ratio >0.5, hyperchromasia, membrane irregularity (arrow), (b) acute inflammation, reactive cells (curved arrow). Nuclear–cytoplasmic ratio >0.5, hyperchromasia, nuclear membrane irregularity (arrow), (c) nuclear–cytoplasmic ratio >0.5, nuclear irregularity (arrow). Enlarged nuclei, membrane irregularity, nuclear–cytoplasmic ratio <0.5 (arrowhead), and (d) crystals, acute inflammation, nuclear hyperchromasia, irregularity (arrow). Degenerated cells with irregular nuclei, nuclear–cytoplasmic ratio ≤ 0.5 (arrowhead)Figure 3: Biopsy-proven high-grade urothelial carcinoma not meeting required criteria by The Paris System of nuclear–cytoplasmic ratio >0.7 (a) and severe nuclear hyperchromasia (b)

Figure 2: Focal subtle atypia in biopsy-proven high-grade urothelial carcinoma cases with initial negative high-grade urothelial carcinoma, (a) acute inflammation, crystals, reactive cells (curved arrow). Nuclear–cytoplasmic ratio >0.5, hyperchromasia, membrane irregularity (arrow), (b) acute inflammation, reactive cells (curved arrow). Nuclear–cytoplasmic ratio >0.5, hyperchromasia, nuclear membrane irregularity (arrow), (c) nuclear–cytoplasmic ratio >0.5, nuclear irregularity (arrow). Enlarged nuclei, membrane irregularity, nuclear–cytoplasmic ratio <0.5 (arrowhead), and (d) crystals, acute inflammation, nuclear hyperchromasia, irregularity (arrow). Degenerated cells with irregular nuclei, nuclear–cytoplasmic ratio ≤ 0.5 (arrowhead)Figure 3: Biopsy-proven high-grade urothelial carcinoma not meeting required criteria by The Paris System of nuclear–cytoplasmic ratio >0.7 (a) and severe nuclear hyperchromasia (b)